These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30355587)

  • 61. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.
    Bell MD; Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
    World J Urol; 2016 Oct; 34(10):1405-9. PubMed ID: 26906030
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
    Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
    Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Urine cytology and urine markers. Significance for clinical practice].
    Tritschler S; Zaak D; Knuechel R; Stief CG
    Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Zuiverloon TCM; de Jong FC; Theodorescu D
    Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 68. FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence.
    Blanca A; Requena MJ; Alvarez J; Cheng L; Montironi R; Raspollini MR; Reymundo C; Lopez-Beltran A
    Biomark Med; 2016; 10(3):243-53. PubMed ID: 26861974
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
    Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
    Urol Oncol; 2015 Feb; 33(2):66.e25-31. PubMed ID: 25037483
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
    JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the diagnostic accuracy of UBC
    Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
    Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical usefulness of the ImmunoCyt urinary test in the follow-up protocol of patients with urothelial neoplasms].
    García Peñalver C; Pérez Barrios A; Leiva Galvis O
    Actas Urol Esp; 2005 Jun; 29(6):535-41. PubMed ID: 16092675
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
    Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
    Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery.
    Gómez Del Cañizo C; González Ginel I; Martín-Arriscado Arroba C; de la Calle Moreno A; Hernández Arroyo M; Rodríguez Antolín A; Guerrero Ramos F
    Urol Oncol; 2024 Aug; 42(8):246.e15-246.e21. PubMed ID: 38664179
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
    Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
    Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.
    Mengual L; Frantzi M; Mokou M; Ingelmo-Torres M; Vlaming M; Merseburger AS; Roesch MC; Culig Z; Alcaraz A; Vlahou A; Mischak H; Van der Heijden AG
    Br J Cancer; 2022 Nov; 127(11):2043-2051. PubMed ID: 36192490
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
    Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
    Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.